Two important considerations for understanding how estrogen inhibitors suppress lung cancer development are as follows: first, selective estrogen receptor modulators such as tamoxifen, commonly used in breast cancer treatment, can act as agonists or antagonists of estrogen receptors depending on the cell type and promoter elements [32,106,107]. This evidence concerns the gene ESR1 and lung carcinoma.